Focused On-demand Library for Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q14738

UPID:
2A5D_HUMAN

ALTERNATIVE NAMES:
PP2A B subunit isoform B'-delta; PP2A B subunit isoform B56-delta; PP2A B subunit isoform PR61-delta; PP2A B subunit isoform R5-delta

ALTERNATIVE UPACC:
Q14738; A8K3I9; B5BUA6; O00494; O00696; Q15171; Q5TC39

BACKGROUND:
The Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform, also referred to as PP2A B subunit isoform B56-delta, is instrumental in directing the localization and activity of the catalytic enzyme to specific cellular compartments. Its ability to influence enzyme activity and substrate specificity is vital for maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its association with Intellectual developmental disorder, autosomal dominant 35, the protein represents a promising avenue for research into genetic disorders. The exploration of Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform's function could lead to groundbreaking therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 851 of 8789